Karmanos Cancer Institute | Strategic Alliance Partners

Rina-S led to a 50% response rate, including two complete responses, in heavily pretreated advanced endometrial cancer, according to early trial findings.

The Food and Drug Administration has approved Onivyde with oxaliplatin, fluorouracil and leucovorin, for the first-line treatment of patients with metastatic pancreatic adenocarcinoma, the agency has announced.